Highest-materiality recent filing
PetVivo receives final $600K installment of $1M equity financing; issues 1.25M units at $0.80/unit
Received $600K on April 15, 2026 as final payment under March 13 Subscription Agreement, completing $1M total investment.
PetVivo raises $1M via unit offering with warrants; $1.5M option available
Raised $1M from 1.25M units at $0.80/unit; each unit = 1 restricted common share + 1 warrant at $1.10/strike, 3-year term.
PetVivo raises $1M in private placement, secures option for additional $1.5M
Issued 1,250,000 restricted common shares and warrants at $0.80/unit for $1M; $400K received Mar 13, 2026.
PetVivo Holdings files 8-K with investor presentation; no material new info disclosed
Company furnished investor presentation under Item 7.01 Regulation FD on March 3, 2026.
Director Spencer Breithaupt resigns from PetVivo board; vacancy left unfilled
Spencer Breithaupt resigned from the Board effective January 26, 2026; no disagreement with the Company.
PetVivo files 8-K to furnish investor presentation; no specific details provided
Filing filed under Item 7.01 for Regulation FD disclosure; presentation not included in text.
PetVivo director Michael Eldred resigns from board, vacancy left unfilled
Michael Eldred resigned from PetVivo's Board of Directors effective January 9, 2026; no disagreement cited.
PetVivo provides investor presentation; no specific financial data available in filing
Company made investor presentation dated November 2025 available for conferences.
PetVivo expands board to eight, appoints Josh Ruben as director
Board size increased from 7 to 8; Josh Ruben appointed independent director effective October 28, 2025.
PetVivo converts $2.02M debt into 3.67M shares via note conversion agreements
Four shareholders converted $2,018,155 aggregate debt (principal $1.85M + interest $168,155) into 3,669,806 restricted shares.
PetVivo receives final $1M from $5M Series B Convertible Preferred Stock offering
Received $1M from full exercise of Purchase Option, completing $5M equity financing.
PetVivo receives $3M from partial exercise of Series B convertible preferred stock purchase option
Received $3,000,000 from partial exercise of Purchase Option; total proceeds to date $4,000,000 out of $5,000,000 offering.
PetVivo receives $200K from partial exercise of Series B Convertible Preferred purchase option
Received $200,000 on June 16, 2025; total $1,000,000 received under $5M Series B Preferred offering.
PetVivo issues $160K promissory note with warrant; conversion at $0.75/share
Note principal $160,000 at 10% annual interest, matures Dec 31, 2025.
Received $200,000 on May 6, 2025 from partial exercise of Purchase Option under March 26 Subscription Agreement.
PetVivo replaces auditor after Assurance Dimensions exits public-company audit practice
Assurance Dimensions resigned April 1, 2025, citing exit from providing audit services to public companies.
PetVivo raises $5M via Series B Convertible Preferred Stock; initial $600K funded
$5M Series B Convertible Preferred offering at $1.00/share; $600K initial, option for additional $4.4M.
PetVivo raises $5M in Series B convertible preferred stock financing
Initial $600K received; investor may purchase remaining $4.4M by May 27, 2025.
PetVivo extends CEO term to 2027, cuts base salary to $150K
Term extended to March 31, 2027; base salary set at $150,000 per year, retroactive to May 1, 2024.
PetVivo borrows $200K from director Michael Eldred at 12% interest; issues 100K-share warrant
Principal $200,000, 12% annual interest, maturity on or about September 3, 2025.
Effective March 1, 2025, subsidiary PetVivo, Inc. renamed to PetVivo Animal Health, Inc.
PetVivo signs exclusive license for VetStem's PrecisePRP canine and equine products
Upfront license fee of $500,000; milestone payments up to $500,000 in $250,000 increments.
PetVivo raises $500K via convertible notes at 10% interest to fund VetStem license
Two existing shareholders lend $300K and $200K, maturing Feb 14, 2026.
PetVivo raises $617,500 in private placement of 950,000 shares at $0.65/share
Sold 950,000 restricted common shares at $0.65 each to ~8 accredited investors.
PetVivo eliminates COO role, terminates employment of Randall A. Meyer
Position of Chief Operating Officer eliminated effective January 31, 2025 as part of cost-cutting initiatives.
PetVivo furnishes January 2025 investor presentation; no material new details disclosed
Filed under Item 7.01 for Regulation FD; presentation intended for investor conferences.
PetVivo Holdings files 8-K to furnish investor presentation; no material new information identified
Company furnishes December 2024 investor presentation under Regulation FD; presentation content not provided in this analysis.
PetVivo adopts non-employee director compensation policy for FY2025; aggregate cost ~$223K
Each non-employee director receives $10,000 annual cash retainer, payable quarterly as cash flow permits.
PetVivo Chairman James Martin passes away on September 28, 2024
James Martin, Chairman of the Board, died peacefully on September 28, 2024.
PetVivo appoints Mike Eldred to board, expanding from seven to eight directors
Board increased to eight directors, effective Sep 25, 2024; Eldred fills new seat.
PetVivo Holdings delisted from Nasdaq; securities to trade on OTCQB
Nasdaq filed Form 25 on Sept 6, 2024 to delist PETV and PETVW due to noncompliance with Listing Rule 5550(b).
PetVivo to delist from Nasdaq, begin trading on OTCQB on July 29
Nasdaq Board declined to review delisting decision on July 25, 2024; company will not appeal to SEC.
PetVivo raises $1.21M via private placement of Series A Preferred and warrants at $0.40/unit
Raised $1,210,000 by selling 3,025,000 units at $0.40/unit to 3 accredited investors.
PetVivo FY2024 revenue up 6% to $969K; net loss widens to $11.0M; FY2025 guidance $1.5-$2.0M
Revenue $969K (+6% YoY); gross margin 76.3% (+40 bps).
PetVivo raises $1.1M via private placement of common stock and warrants; also converts $300K note
Company sold 1,567,857 units at $0.70 each to 10 accredited investors, raising $1,097,500.
PetVivo converts $300K note from 10% holder into 430,798 units (share + warrant) at $0.70/unit
Converted $300,000 principal plus $1,558 accrued interest into 430,798 Units at $0.70/Unit.
PetVivo COO salary cut to $150k; three execs total reduction 50.6%
COO Randall Meyer salary reduced from $270,000 to $150,000, effective May 1, 2024.
PetVivo launches cost reduction program; CEO and CBDO/GC salaries cut
CEO John Lai salary reduced from $350,000 to $150,000 per year, effective May 1, 2024.
PetVivo grants CEO John Lai 150,000 RSUs at $0.60/share, fully vested
150,000 RSUs granted to CEO John Lai at $0.60 per share, aggregate value $90,000.
PetVivo enters $300K convertible note with major shareholder at $0.70/unit
$300K note from >10% holder A.L. Sarroff Fund; 10% interest, matures May 10, 2024.
PetVivo receives Nasdaq delisting notice; trading suspended April 9; appeals ongoing
Nasdaq Panel determined PetVivo failed to comply with $2.5M stockholders' equity rule by April 1, 2024.
PetVivo appoints Garry Lowenthal as CFO with $200k salary and 90,000 RSUs
Mr. Lowenthal appointed CFO effective March 8, 2024; base salary $200,000 paid to his holding company.
PetVivo terminates ATM sales agreement with ThinkEquity; raised $959k prior
ATM Agreement with ThinkEquity LLC terminated effective March 7, 2024.
PetVivo dual lists common stock on Upstream exchange for non-U.S. investors
Trading under ticker PETV on Upstream began March 5, 2024 at 10:00am EST.
PetVivo Q3 revenue up 17% YoY to $596K; net loss narrows to $1.75M
Revenue $595,891 vs $510,109 YoY; new Covetrus distribution contributed $106K, MWI sales $440K.
PetVivo major shareholder converts $123,255 note into 164,340 shares at $0.75/share
Alan Sarnoff, a >10% shareholder, converted $120,000 principal plus $3,255 accrued interest into 164,340 restricted shares at $0.75/share.
PetVivo Holdings names audit, compensation and governance committee members
Audit Committee: Robert Costantino (Chair), Joseph Jasper, James Martin (all independent).
PetVivo raises $1.25M in private placement of units at $0.90/unit
Sold 1,386,469 units to 13 accredited investors at $0.90 per unit.
PetVivo CFO Robert Folkes resigns effective Feb 2, 2024; will assist during transition
Robert J. Folkes resigns as CFO, effective February 2, 2024.
By eliminating the position of COO, the Board also terminated the employment of Randall A. Meyer, effective immediately;
On September 28, 2024, James Martin, a director and Chairman of the Board of PetVivo Holdings, Inc. (the “Company”), peacefully passed away.
Effective as of September 25, 2024, the Board of Directors of PetVivo Holdings, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Mike Eldred as a member of the Board to fill the vacancy created by the increase in size of the Board.
led by Garry Lowenthal, the Company’s new Chief Financial Officer.
On March 8, 2024, PetVivo Holdings, Inc. (the “Company”) appointed Garry Lowenthal to serve as the Company’s Chief Financial Officer.
he will be resigning as Chief Financial Officer (“CFO”) of the Company, effective as of February 2, 2024.
Max materiality 0.90 · Median 0.50 · Most common event other_material